Benefits Brief interviews David Williams on employer drug costs

Employers are struggling with drug costs and having trouble driving return on investment on GLP-1s. Benefit Brief News (Employers Rethink Drug Benefits As GLP-1 Coverage Forces More Active Cost Management) interviewed Health Business Group President, David E. Williams on the topic.

"With GLP-1s, the employer’s costs are definitely higher in the first year. Then, if that employee leaves in three years, any long-term health benefit accrues to somebody else. The most likely scenario is that they stop taking the drug and gain the weight back, which negates the investment. This is the crux of what employers are facing," Williams says.